ssr免费订阅地址
CURRENT
ISSUE
1603
July 27, 2023
Lumateperone (Caplyta) for Schizophrenia

The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.

STANDARD TREATMENT — Antipsychotic drugs are more effective in treating the positive symptoms of schizophrenia (agitation, hallucinations, delusions) than the negative symptoms (apathy, social withdrawal, blunted affect).1 Second-generation antipsychotic drugs are generally used for initial treatment of schizophrenia, even though controlled trials have generally failed to...  Continue reading

More from Issue 1603
  • Durysta - A Bimatoprost Implant for Glaucoma
  • Drugs Past Their Expiration Date
  • Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy
ssr免费订阅地址
Previous Issue: 1602      July 13, 2023
  • Drugs for Postmenopausal Osteoporosis
  • Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)
View Complete Issue
Previous Issues arrow
Coming Soon
IV Artesunate for Severe Malaria
Drugs for Menopausal Symptoms
Cenobamate (Xcopri) for Epilepsy
Phexxi - A Nonhormonal Contraceptive Gel
Ozanimod (Zeposia) for Multiple Sclerosis
Search
advanced search 酸酸乳ssr网站
Donate
Subscribe
Conversation
Follow us   Twitter ssr网站 YouTube 一元机场网址ssr RSS   Email Alerts
Advance Release
ADVANCE
RELEASE
In Brief: An Asenapine Patch (Secuado) for Schizophrenia

A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since ... Continue reading

 Tweets
Tweets by @MedicalLetter
电脑如何连接外国网站  讯飞手游游戏加速器  黑洞加速器苹果  蚂蚁免费加速器app葡京  急速vpn  电脑PC端的免费梯子  北极星vp加速器